Tesamorelin

Overview

Tesamorelin is one of the few therapeutic peptides that's actually FDA-approved — and that distinction matters enormously. While most peptides in this space exist in a gray zone of compounding pharmacy access or research-only status, tesamorelin earned a genuine approval in November 2010 for a specific, well-documented problem: the accumulation of excess visceral abdominal fat in HIV-positive patients with lipodystrophy.[1]

It's a synthetic analog of growth hormone-releasing hormone (GHRH) — the signal your hypothalamus sends to your pituitary gland when it wants more growth hormone produced. Tesamorelin mimics that signal, prompting your pituitary to release GH in a pulse pattern that's much closer to natural physiology than direct GH injections. That mechanism is why it's attracted interest well beyond its approved indication.

Sold under the brand names EGRIFTA SV and EGRIFTA, it's prescribed by HIV specialists and, increasingly, discussed in the context of broader metabolic and body composition optimization. What the evidence actually supports — and where it runs out — is worth understanding clearly before you read anything else on this page.

Mechanism of Action

GHRH receptor agonist → stimulates endogenous GH secretion

Your hypothalamus releases GHRH in pulses throughout the day — most prominently during deep sleep — which signals the pituitary gland to secrete growth hormone. GH then travels to the liver and other tissues, triggering the production of IGF-1 (insulin-like growth factor 1). IGF-1 is the primary downstream driver of GH's effects on body composition: it promotes lipolysis (fat breakdown) and lean mass preservation.

Tesamorelin is a stabilized synthetic version of the 44-amino acid GHRH peptide. The natural GHRH molecule degrades rapidly in plasma — its half-life is only a few minutes — which makes it impractical as a therapeutic. Tesamorelin addresses this by adding a trans-3-hexenoic acid group to the N-terminus of the peptide, which protects it from dipeptidyl peptidase IV (DPP-IV) degradation and extends its functional duration.[3]

When you inject tesamorelin subcutaneously, it binds to GHRH receptors on somatotroph cells in the anterior pituitary. Those cells respond by synthesizing and releasing GH. The GH pulse then drives IGF-1 production, and elevated IGF-1 levels are what produce the visceral fat reduction seen in trials.

Critically, tesamorelin doesn't bypass the pituitary's feedback mechanisms. If IGF-1 levels rise too high, the pituitary responds by reducing GH output — the same negative feedback loop that operates normally. This self-regulating quality is part of why its side effect profile differs from exogenous GH administration, where you're overriding that feedback entirely.

What the Evidence Shows

The foundational evidence comes from two Phase 3 randomized, placebo-controlled trials that supported the 2010 FDA approval. Both enrolled HIV-positive adults with lipodystrophy and measurable visceral fat accumulation, and both used 2 mg/day subcutaneous tesamorelin over 26 weeks.[2]

Across these trials, tesamorelin produced statistically significant reductions in visceral adipose tissue measured by CT scan. The VAT reduction was clinically meaningful — not just a marginal statistical signal — and was accompanied by improvements in the waist-to-hip ratio and patient-reported body image outcomes.[3]

A 2024 study published in AIDS examined tesamorelin's efficacy specifically in people with HIV who are on integrase inhibitor (INSTI)-based regimens — the current standard of care for most HIV patients, since the original Phase 3 trials predate INSTIs' dominance.[4] That's an important gap to fill, because antiretroviral regimens affect metabolic parameters, and a drug tested on older regimens might perform differently in today's patients. The 2024 data supported tesamorelin's continued efficacy in this updated treatment context.[4]

What the trials also showed: the VAT reduction is not permanent. Patients who discontinued tesamorelin after 26 weeks saw visceral fat return toward baseline over the following months.[3] This isn't a drug you take for a cycle and then stop — maintaining the benefit requires ongoing treatment, which has real implications for cost, access, and long-term safety monitoring.

Triglyceride levels and some lipid parameters improved in treated patients alongside VAT reduction, which matters because HIV lipodystrophy carries elevated cardiovascular risk.[3] Whether those lipid improvements translate to hard cardiovascular outcomes hasn't been established in a dedicated outcomes trial.

Side Effects
Tesamorelin's side effect profile reflects its mechanism: you're raising GH and IGF-1, and the consequences of that elevation — however physiologically patterned — are what drive most adverse effects.

If you develop significant edema, new joint pain that's worsening over weeks, or any signs of glucose dysregulation (increased thirst, frequent urination, fatigue), that's worth a conversation with your prescriber — not something to wait out.